Equities research analysts expect that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will report ($0.76) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Sunesis Pharmaceuticals’ earnings. Sunesis Pharmaceuticals reported earnings per share of ($0.72) during the same quarter last year, which suggests a negative year over year growth rate of 5.6%. The firm is scheduled to issue its next quarterly earnings results on Friday, August 4th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($2.74) to ($1.45). For the next year, analysts anticipate that the firm will report earnings of ($2.18) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.36. Sunesis Pharmaceuticals had a negative return on equity of 806.43% and a negative net margin of 1,623.12%. The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter last year, the company earned ($0.12) earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year.

A number of equities analysts recently weighed in on SNSS shares. Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $4.50 price target for the company in a report on Thursday, January 19th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Tuesday, May 2nd.

Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 0.96% on Monday, hitting $3.10. The stock had a trading volume of 57,096 shares. The company has a 50 day moving average price of $3.69 and a 200-day moving average price of $3.90. Sunesis Pharmaceuticals has a 52-week low of $2.63 and a 52-week high of $6.30. The company’s market cap is $64.86 million.

COPYRIGHT VIOLATION WARNING: “-$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/15/0-76-earnings-per-share-expected-for-sunesis-pharmaceuticals-inc-snss-this-quarter.html.

Institutional investors have recently made changes to their positions in the stock. Great Point Partners LLC purchased a new position in shares of Sunesis Pharmaceuticals during the third quarter worth approximately $4,648,000. Baker BROS. Advisors LP purchased a new position in shares of Sunesis Pharmaceuticals during the third quarter worth approximately $3,241,000. Boxer Capital LLC purchased a new position in shares of Sunesis Pharmaceuticals during the fourth quarter worth approximately $1,901,000. Vivo Capital LLC purchased a new position in shares of Sunesis Pharmaceuticals during the fourth quarter worth approximately $1,810,000. Finally, Vanguard Group Inc. boosted its position in shares of Sunesis Pharmaceuticals by 35.0% in the first quarter. Vanguard Group Inc. now owns 581,940 shares of the biopharmaceutical company’s stock worth $2,386,000 after buying an additional 150,994 shares during the last quarter. 34.30% of the stock is owned by institutional investors and hedge funds.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

5 Day Chart for NASDAQ:SNSS

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.